Search
Ferumoxides
go.drugbank.com/drugs/DB09508ApprovedCategories: Compounds used in a research, industrial, or household settingCamibirstat
go.drugbank.com/drugs/DB21586InvestigationalCamibirstat has a monoisotopic molecular weight of 562.17 Da. … Camibirstat is under investigation in clinical trial NCT04891757 (FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies).
CX501
go.drugbank.com/drugs/DB05174InvestigationalIt is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of
Iomethin I-125
go.drugbank.com/drugs/DB20779ExperimentalIomethin I-125 has a monoisotopic molecular weight of 353.05 Da.
Florquinitau (18F)
go.drugbank.com/drugs/DB19215ApprovedInvestigationalon PET images. … [L64052,L64053] It is the second fluorine-18 tau PET imaging agent approved in the United States, after flortaucipir (Tauvid), which was approved in 2020.[L64054,L14114]
Telratolimod
go.drugbank.com/drugs/DB19590InvestigationalTelratolimod has a monoisotopic molecular weight of 593.47 Da. … Telratolimod is under investigation in clinical trial NCT06680479 (Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
Rezivertinib
go.drugbank.com/drugs/DB21471InvestigationalRezivertinib has a monoisotopic molecular weight of 486.24 Da. … Rezivertinib is under investigation in clinical trial NCT06955325 (Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations).
Tuxobertinib
go.drugbank.com/drugs/DB21508InvestigationalTuxobertinib has a monoisotopic molecular weight of 560.19 Da. … Tuxobertinib is under investigation in clinical trial NCT04209465 (A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.).
Dibekacin
go.drugbank.com/drugs/DB13270ApprovedDibekacin is an aminoglycoside antibiotic marketed in Japan [L5623].
R1295
go.drugbank.com/drugs/DB05122ExperimentalR1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. … Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.